U.S. Patients Travel to China for Cancer Drugs Awaiting FDA Market Entry

By Arthur Allen · KFF Health News · 2026-10-20

According to reporting from KFF Health News, American cancer patients are increasingly sourcing treatments directly from China to bypass domestic regulatory delays. While the FDA recently licensed the lung cancer drug sunvozertinib, its absence from the U.S. market has forced fam

According to reporting from KFF Health News, American cancer patients are increasingly sourcing treatments directly from China to bypass domestic regulatory delays. While the FDA recently licensed the lung cancer drug sunvozertinib, its absence from the U.S. market has forced fam